NCT02159859View on ClinicalTrials.gov

Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
End Stage Renal Disease
Interventions
DRUG

Ertapenem

Subjects are hemodialysis patients who are admitted to Oakwood Hospital - Dearborn

Trial Locations (1)

48124

Oakwood Hospital - Dearborn, Dearborn

All Listed Sponsors
collaborator

Wayne State University

OTHER

lead

William Beaumont Hospitals

OTHER

NCT02159859 - Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients | Biotech Hunter | Biotech Hunter